問卷

TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Neurology

Chi Mei Medical Center (在職)

Division of Neurology

更新時間:2023-09-19

林高章
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

9Cases

2019-08-19 - 2024-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2016-02-01 - 2020-04-02

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate LY2951742 in patients with chronic migraine — the REGAIN trial.
  • Condition/Disease

    Chronic migraine

  • Test Drug

    LY2951742

Participate Sites
5Sites

Terminated5Sites

2007-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-07-01 - 2020-06-09

Phase III

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia
  • Condition/Disease

    Trigeminal Neuralgia

  • Test Drug

    BIIB074

Participate Sites
5Sites

Not yet recruiting5Sites

2016-02-01 - 2018-06-17

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
  • Condition/Disease

    Episodic Migraine

  • Test Drug

    LY2951742

Participate Sites
6Sites

Terminated6Sites

2019-09-01 - 2022-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2015-03-01 - 2017-05-31

Phase III

AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH POST-HERPETIC NEURALGIA FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION
  • Condition/Disease

    POST-HERPETIC NEURALGIA

  • Test Drug

    DS-5565

Participate Sites
14Sites

Terminated14Sites